Jennifer Curtis

1.6k total citations
15 papers, 672 citations indexed

About

Jennifer Curtis is a scholar working on Reproductive Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Jennifer Curtis has authored 15 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Reproductive Medicine, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Jennifer Curtis's work include Ovarian cancer diagnosis and treatment (9 papers), Chromatin Remodeling and Cancer (5 papers) and Cancer Mechanisms and Therapy (3 papers). Jennifer Curtis is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), Chromatin Remodeling and Cancer (5 papers) and Cancer Mechanisms and Therapy (3 papers). Jennifer Curtis collaborates with scholars based in United States, Finland and Israel. Jennifer Curtis's co-authors include Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos, Miguel Regueiro, Scott E. Plevy, Neil S. Horowitz, Richard T. Penson, Don S. Dizon, Cesar M. Castro and Christina I. Herold and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jennifer Curtis

15 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Curtis United States 10 408 321 239 123 88 15 672
M.G. Federici United States 9 225 0.6× 374 1.2× 128 0.5× 63 0.5× 103 1.2× 11 688
Monjri M. Shah United States 12 247 0.6× 264 0.8× 231 1.0× 34 0.3× 52 0.6× 13 613
Suzanna L. Arcand Canada 18 261 0.6× 465 1.4× 141 0.6× 59 0.5× 184 2.1× 26 760
Anthony Miliotto United States 13 559 1.4× 255 0.8× 78 0.3× 570 4.6× 81 0.9× 23 866
Sandra D. Bohling United States 13 211 0.5× 209 0.7× 37 0.2× 141 1.1× 38 0.4× 22 586
Munmun Rahman Japan 15 178 0.4× 537 1.7× 269 1.1× 47 0.4× 27 0.3× 34 806
C. Weber United States 4 428 1.0× 389 1.2× 33 0.1× 298 2.4× 105 1.2× 7 796
John B. Beard United States 7 110 0.3× 302 0.9× 106 0.4× 168 1.4× 18 0.2× 8 513
Jeffrey P. Bruce Canada 9 264 0.6× 240 0.7× 65 0.3× 61 0.5× 27 0.3× 26 517
Matthew D. Stachler United States 15 320 0.8× 344 1.1× 29 0.1× 117 1.0× 144 1.6× 38 911

Countries citing papers authored by Jennifer Curtis

Since Specialization
Citations

This map shows the geographic impact of Jennifer Curtis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Curtis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Curtis more than expected).

Fields of papers citing papers by Jennifer Curtis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Curtis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Curtis. The network helps show where Jennifer Curtis may publish in the future.

Co-authorship network of co-authors of Jennifer Curtis

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Curtis. A scholar is included among the top collaborators of Jennifer Curtis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Curtis. Jennifer Curtis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Konstantinopoulos, Panagiotis A., Su–Chun Cheng, Elizabeth K. Lee, et al.. (2024). Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO Precision Oncology. 8(8). e2300635–e2300635. 9 indexed citations
2.
Konstantinopoulos, Panagiotis A., Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, et al.. (2023). Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.. Journal of Clinical Oncology. 41(16_suppl). 5512–5512. 3 indexed citations
3.
McQueeney, Kelley E., Jennifer Curtis, Marisa R. Nucci, et al.. (2023). Abstract 162: Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma. Cancer Research. 83(7_Supplement). 162–162. 1 indexed citations
4.
Konstantinopoulos, Panagiotis A., Alexandre André Balieiro Anastácio da Costa, D. Gulhan, et al.. (2021). A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nature Communications. 12(1). 5574–5574. 44 indexed citations
5.
Lee, Elizabeth K., Carol Aghajanian, Robert L. Coleman, et al.. (2020). Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecologic Oncology Reports. 32. 100546–100546. 13 indexed citations
6.
Lee, Elizabeth K., Ursula A. Matulonis, Michael J. Birrer, et al.. (2019). Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic Oncology Reports. 29. 118–122. 14 indexed citations
7.
Konstantinopoulos, Panagiotis A., Joyce F. Liu, Weixiu Luo, et al.. (2019). Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).. Journal of Clinical Oncology. 37(15_suppl). 5502–5502. 7 indexed citations
8.
Barry, William T., Michael J. Birrer, Ronald J. Buckanovich, et al.. (2019). Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Annals of Oncology. 30(4). 551–557. 138 indexed citations
9.
Hendrickson, Andrea E. Wahner, Richard T. Penson, Austin Doyle, et al.. (2019). Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC). Annals of Oncology. 30. v897–v897. 5 indexed citations
10.
Liu, Joyce F., Christina I. Herold, Kathryn P. Gray, et al.. (2019). Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. JAMA Oncology. 5(12). 1731–1731. 175 indexed citations
11.
Herold, Christina I., Wenjie Luo, Richard T. Penson, et al.. (2018). A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer. Annals of Oncology. 29. viii334–viii335. 20 indexed citations
12.
Konstantinopoulos, Panagiotis A., Joyce F. Liu, William T. Barry, et al.. (2017). Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS5615–TPS5615. 6 indexed citations
13.
Choi, Young Eun, Chiara Battelli, Jacqueline Watson, et al.. (2014). Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 5(9). 2678–2687. 47 indexed citations
14.
Schinzel, Anna C., Yaara Zwang, Pratiti Bandopadhayay, et al.. (2014). An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences. 112(1). 232–237. 133 indexed citations
15.
Regueiro, Miguel, Jennifer Curtis, & Scott E. Plevy. (2006). Infliximab for Hospitalized Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology. 40(6). 476–481. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.G. Federici Breakdown of academic impact, for papers by Monjri M. Shah Breakdown of academic impact, for papers by Suzanna L. Arcand Breakdown of academic impact, for papers by Anthony Miliotto Breakdown of academic impact, for papers by Sandra D. Bohling Breakdown of academic impact, for papers by Munmun Rahman Breakdown of academic impact, for papers by C. Weber Breakdown of academic impact, for papers by John B. Beard Breakdown of academic impact, for papers by Jeffrey P. Bruce Breakdown of academic impact, for papers by Matthew D. Stachler
Rankless by CCL
2026